Collegium Pharmaceutical (COLL) Convertible Debt (2020 - 2026)

Collegium Pharmaceutical's Convertible Debt history runs 7 years deep, the most recent figure standing at $238.5 million for Q1 2026.

• On a quarterly basis, Convertible Debt changed 0.44% year-over-year to $238.5 million in Q1 2026; TTM through Mar 2026 was $238.5 million, a 0.44% change from a year earlier, with the FY2025 full-year figure at $238.2 million, changed 0.44% from the prior year.
• Convertible Debt held at $238.5 million in Q1 2026 per COLL's latest filing, from $238.2 million in the prior quarter.
• Across five years, Convertible Debt topped out at $262.4 million in Q1 2024 and bottomed at $26.4 million in Q1 2022.
• The 5-year median for Convertible Debt is $237.7 million (2025), against an average of $215.2 million.
• Across the five-year window, Convertible Debt plunged 81.08% in 2022 and surged 891.35% in 2023, its largest moves.
• Year by year, Convertible Debt stood at $140.9 million in 2022, then soared by 86.07% to $262.1 million in 2023, then dropped by 9.52% to $237.2 million in 2024, then rose by 0.44% to $238.2 million in 2025, then gained by 0.11% to $238.5 million in 2026.
• Per Business Quant, the three latest COLL Convertible Debt figures stand at $238.5 million (Q1 2026), $238.2 million (Q4 2025), and $238.0 million (Q3 2025).